CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

1.889B

Vuru Grade

71.43/100

Current Price

$76.60
-0.31 (-0.40%)

Growth Price

$31.06
Overvalued by 59.45%

Stability Price

$19.39
Overvalued by 74.68%

Company Metrics

  • 30.3 P/E
  • 8.32 P/S
  • 9.76 P/B
  • 2.538 EPS
  • 40.69% Cash ROIC
  • 2.38 Cash Ratio
  • 0 / 0% Dividend
  • 76,179.00 Avg. Vol.
  • 27.57M Shares
  • 1.889B Market Cap.

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

China Biologic Products CBPO) Falls: Stock Goes Down 6%
Zacks.com - Feb 25, 2015
China Biologic Products, Inc. (CBPO - Snapshot Report) saw a big move last session, as the company's shares fell nearly 6% on the day.
China Biologic Products Earnings Preview (CBPO)
Seeking Alpha (registration) - Aug 5, 2014
China Biologic Products (NASDAQ: CBPO), a biopharmaceutical company focused on developing plasma-based products, has been subjected to a roller coaster ride over the last several months. Back in mid June, shares fell more than 11% after the ...
China Biologic Products Becomes Oversold (CBPO)
Forbes - Oct 13, 2014
In trading on Monday, shares of China Biologic Products Inc (NASD: CBPO) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $49.11 per share.
Stock in Focus : China Biologic Products, Inc. (NASDAQ:CBPO)
Markets Wired - Feb 18, 2015
China Biologic Products, Inc. (NASDAQ:CBPO) (TREND ANALYSIS) shares were traded with more than 50% increase in usual volume.
Ups & Downs At Street: China Biologic Products, Inc. (NASDAQ:CBPO), Pingtan ... - eMarketsDaily
Update: China Biologic Products Adopts Stockholder Plan To Avoid Hostile ...
Seeking Alpha - Jan 9, 2015
Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ:CBPO), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued that the company's ...
Why China Biologic Products (CBPO) Could Be an Impressive Growth Stock
Zacks.com - Aug 19, 2014
One such company that might be well-positioned for future earnings growth is China Biologic Products, Inc. (CBPO - Snapshot Report).
China Biologic Products to Report Fourth Quarter and Fiscal Year 2014 ...
CNNMoney - Feb 17, 2015
BEIJING, Feb. 17, 2015 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release ...
Mid-Day Changers: China Biologic Products, Inc. (CBPO), Semler Scientific Inc ... - WallStreet Scope
Declarations in Focus: Discovery Laboratories Inc. (NASDAQ:DSCO), China ... - eMarketsDaily
China Biologic Products' (CBPO) CEO David Gao on Q3 2014 Results ...
Seeking Alpha (registration) - Nov 11, 2014
Hello, everyone and thank you for joining us on today's call. China Biologic announced its quarterly financial results on November 5 after the market closed.
China Biologic Presents A Unique Investment Opportunity
Seeking Alpha (registration) - Sep 22, 2014
Undoubtedly, both China Biologic's majority stake in Guizhou and its two successive quarters of rising product revenues are healthy signs of a rapidly growing healthcare company. Nevertheless, with such impressive growth and incredible stock ...
China Biologic Receives GMP Certification for New Coagulation Factor Facility
PR Newswire (press release) - Dec 23, 2014
BEIJING, Dec. 23, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, ...